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Introduction
Breast cancer is one of the most common malignancies in wom-
en, accounting for almost 1 in 3 diagnosed cancers, and it is the 
second leading cause of cancer death among women in Western 
countries (1). Five percent to ten percent of all breast cancer cas-
es have a hereditary component, and thirty percent to eighty per-
cent of all hereditary cases are attributable to mutations in the 
breast cancer 1 or breast cancer 2 (BRCA1 or BRCA2) gene. Ger-
mline mutations in the BRCA1 gene predispose women to hered-
itary breast and ovarian cancer (HBOC), with an 80%–90% 
lifetime risk of developing breast cancer and a 40%–50% risk of 
developing ovarian cancer (2).
Germline BRCA1 mutations are scattered throughout the 
81-kb-long gene that encompasses 22 coding exons (3). Most of 
the known pathogenic BRCA1 mutations are predicted to result in 
premature termination of protein translation and nonsense-medi-
ated mRNA decay (NMD) (4, 5). These mutations include small 
deletions and insertions that generate frameshifts, single-base 
substitutions that produce termination codons, and splice site 
errors (2). Although there are many different BRCA1 mutations, in 
certain ethnic populations, only a few founder mutations account 
for almost all BRCA1-associated breast and/or ovarian cancer 
families. Two founder mutations, BRCA1185delAG and BRCA15382insC, 
account for the vast majority of BRCA1 mutations in the Ashkenazi 
Jewish population (2, 6). The BRCA1185delAG and BRCA15382insC muta-
tions are carried, respectively, by 1% and 0.15% of Ashkenazi Jews 
(7, 8). The prevalence of these mutations in unselected patients of 
Ashkenazi Jewish ethnicity who have ovarian cancer was found to 
be close to 30% and may even exceed 50% in patients with a fam-
ily history of breast and/or ovarian cancer (9–11).
BRCA1 has been implicated in various cellular processes, 
including DNA repair, cell-cycle control, and transcriptional 
regulation (12). In particular, the role of BRCA1 in homologous 
recombination–mediated (HR-mediated) repair of DNA double- 
strand breaks (DSBs) appears to be important in the maintenance 
of genomic stability and tumor suppression (13). Impaired HR 
also renders BRCA1-deficient cells extremely sensitive to DSB- 
inducing agents, like platinum drugs (14). In line with this, patients 
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Results
Generation of Brca1185stop and Brca15382stop alleles. In order to mimic 
the human BRCA1185delAG and BRCA15382insC mutations in mice, we 
used short, synthetic, single-stranded oligodeoxyribonucleotides 
to introduce mutations into the genome of mouse embryonic stem 
cells (mESCs). It has previously been shown that this technique 
requires (transient) suppression of DNA mismatch repair (MMR) by 
knockdown of Mlh1 or knockout of Msh2 or Msh3 (44–47). In order 
to mimic the BRCA1185delAG mutation, we introduced the Brca1185stop 
mutation into Mlh1-knockdown mESCs by substitution of 3 nucleo-
tides (TCC to AAG), thereby creating an early STOP codon at aa 24 
(Figure 1A). We used Msh3-knockout mESCs to insert 4 nucleotides 
(AGGA) to generate the Brca15382stop mutation, which resulted in 
premature protein truncation at aa 1713 and closely resembled the 
human BRCA15382insC mutation (Figure 1B). Brca1185stop and Brca15382stop 
mutant mESCs were injected into 3.5-day-old C57BL/6J blasto-
cysts to generate chimeric mice. Chimeric mice were mated with 
FVB female mice, and germline transmission of the mutant alleles 
was verified by melting-curve genotyping, PCR, and sequencing 
(Figure 1, C and D, and data not shown).
Embryonic lethality of homozygous Brca1185stop and Brca15382stop 
mice. To determine the effect of the Brca1185stop and Brca15382stop 
mutations on normal mouse development, we intercrossed het-
erozygous Brca1185stop or Brca15382stop mice to produce homozy-
gous offspring. No homozygous pups were born (Supplemental 
Table 1; supplemental material available online with this article; 
doi:10.1172/JCI70196DS1), indicating that homozygous Brca1185stop 
or Brca15382stop mutations lead to embryonic lethality. To study at 
which stage of embryonic development homozygous Brca1185stop 
and Brca15382stop mice die, embryos were harvested and genotyped 
at several time points after gestation. Although (resorbed) homo-
zygous Brca1185stop and Brca15382stop embryos could still be recovered 
from E12.5 to E13.5 (Supplemental Table 1), they were already 
severely delayed in development at E9.5 compared with WT and 
heterozygous embryos (Figure 1, E and F).
Mammary tumor development in K14-Cre Brca1fl/185stop p53fl/fl 
and K14-Cre Brca1fl/5382stop p53fl/fl mice. To investigate the influ-
ence of Brca1185stop and Brca15382stop mutations on tumor develop-
ment, we independently introduced both alleles into the K14-Cre 
Brca1fl/fl p53fl/fl mouse model (referred to hereafter as KB1P mice), 
in which epithelium-specific deletion of Brca1fl and p53fl alleles 
predisposes mice to mammary and skin tumor formation (48). The 
resulting mice carry 1 Brca1185stop or 1 Brca15382stop allele throughout 
their body and sporadically lose the remaining Brca1 WT allele in 
specific tissues, including mammary gland. We crossed heterozy-
gous Brca1185stop and Brca15382stop mice with KB1P animals to generate 
cohorts of K14-Cre Brca1fl/185stop p53fl/fl mice [referred to hereafter as 
KB1(185stop)P mice], K14-Cre Brca1fl/5382stop p53fl/fl [referred to here-
after as KB1(5382stop)P mice], and KB1P littermate controls. The 
3 cohorts were monitored for spontaneous tumor formation and 
showed equal rates of tumor-free survival (TFS) (Figure 2A). For 
all cohorts, the median TFS was approximately 200 days, which 
is similar to what has been described previously for KB1P mice 
(48) and for mice carrying the Brca1C61G mutation (43). In addi-
tion, no obvious differences in TFS could be detected between 
cohorts when only mammary tumors (Figure 2B) or skin tumors 
(Supplemental Figure 1A) were taken into account. Mammary and 
with BRCA1-mutated ovarian cancer had a better prognosis after 
platinum-based chemotherapy than did nonmutation carriers 
(15–18). More recently, it was also shown that triple-negative 
breast cancers in BRCA1 mutation carriers were highly sensitive 
to neoadjuvant cisplatin chemotherapy (19). Moreover, patients 
harboring breast tumors with a BRCA1-like genomic profile had a 
significantly greater benefit from high-dose, platinum-based che-
motherapy versus conventional chemotherapy than did patients 
with non-BRCA1–like tumors (20). Also, chemical inhibitors of 
poly(ADP-ribose) polymerase (PARP), an enzyme involved in DNA 
single-strand break (SSB) repair, are effective against BRCA-defi-
cient tumors in preclinical models (21–23) and in patients carrying 
BRCA mutations (24–29). Recently, the clinical PARP inhibitor 
olaparib (Lynparza) has been approved as maintenance therapy 
for BRCA mutation carriers with platinum-sensitive ovarian can-
cer (30). PARP inhibition results in an increased number of DSBs 
due to replication fork collapse at SSBs. PARP inhibition is there-
fore selectively toxic in cells that lack HR-mediated DSB repair, 
such as BRCA1/2-deficient tumor cells.
The BRCA1 gene encodes for a protein of 1863 aa that con-
tains a highly conserved amino-terminal really interesting new 
gene (RING) domain and tandem BRCA1 C-terminus domain 
(BRCT) repeats at its carboxyl terminus (31). The RING domain 
of BRCA1 is required for stable interaction with BRCA1-associ-
ated RING domain 1 (BARD1), and the BRCA1/BARD1 heterod-
imer has E3 ubiquitin ligase activity with the class of UBCH5 E2 
ubiquitin–conjugating enzymes (32, 33). The observation that 
BRCA1/BARD1-dependent ubiquitin conjugates occur at DSBs 
suggests that the BRCA1/BARD1 heterodimer is important for 
DNA repair and thereby for the tumor-suppressive function of 
BRCA1 (34). BRCA1 has been reported to interact with numerous 
other proteins involved in DNA repair, cell-cycle checkpoint con-
trol, transcription, and chromatin remodeling, mainly through 
its BRCT domains (35–40).
Recent studies have shown that not all biochemical activities 
of BRCA1 are equally important for its role in tumor suppression 
and therapy response (41). Using genetically engineered mouse 
models, Shakya and coworkers showed that loss of BRCA1 E3 
ligase activity does not lead to tumor formation, while loss of 
BRCT phosphoprotein binding does (42). We showed that BRCA1 
RING function is essential for tumor suppression, but does not 
lead to hypersensitivity to homologous recombination deficien-
cy–targeting (HRD-targeting therapy (43). Mouse mammary 
tumors that express a mutant BRCA1-C61G protein, which lacks 
a functional RING domain, respond much worse to DSB-inducing 
therapy than do Brca1-null tumors. In addition, tumors carrying 
the Brca1C61G mutation rapidly develop therapy resistance, while 
retaining the Brca1 mutation. These data suggest that the mutant 
BRCA1-C61G protein has some residual activity in the DNA dam-
age response. This may not only hold true for the BRCA1C61G mis-
sense mutation, but also for other BRCA1 mutations, and could 
indicate the existence of differences in therapeutic response and 
resistance between different BRCA1 mutation carriers.
In the present study, we investigated the effects of the 2 
most common BRCA1 frameshift mutations, BRCA1185delAG and 
BRCA15382insC, on tumor development and therapy response and 
resistance in genetically engineered mouse models.
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ma, characterized by the presence of spindle-shaped cells (Figure 
2C and Supplemental Figure 1, E and F). Other mammary tumors 
that developed in KB1(185stop)P, KB1(5382stop)P, and KB1P mice 
were grouped as lumen-forming carcinomas with varying degrees 
of glandular differentiation (Figure 2C and Supplemental Figure 
1, E and F). Like the majority of human BRCA1–mutated breast 
cancers (49), most KB1(185stop)P and KB1(5382stop)P mammary 
tumors stained negative for the estrogen receptor (Supplemental 
Figure 1, G and H, and Supplemental Table 2).
A high level of genomic instability is one of the hallmarks of 
human BRCA1–associated breast cancer (50), and BRCA1-deficient 
mouse mammary tumors display a considerably larger number of 
genetic aberrations than do BRCA1-proficient tumors (43, 48, 51). 
To investigate the level of genomic instability in KB1(185stop)P and 
KB1(5382stop)P tumors, we measured DNA copy number aber-
rations (CNAs) in mammary tumors from KB1(185stop)P (n = 20), 
skin TFS rates were comparable between KB1P mice derived from 
the 185delAG cohort and from the 5382insC cohort (Supplemen-
tal Figure 1, B and C). Furthermore, the spectrum and incidence 
of tumors that developed were similar among KB1(185stop)P, 
KB1(5382stop)P, and KB1P mice (Supplemental Figure 1D).
Characterization of KB1(185stop)P and KB1(5382stop)P mammary 
tumors. On the basis of their histomorphological characteristics, 
the majority of mammary tumors that developed in KB1(185stop)
P (84%), KB1(5382stop)P (79%), and KB1P mice (85%) were classi-
fied as poorly differentiated, solid carcinomas (Figure 2C and Sup-
plemental Figure 1, E and F). In line with this observation, most 
KB1(185stop)P and KB1(5382stop)P mammary tumors stained (par-
tially) positive for the epithelial marker cytokeratin 8 and negative 
for the mesenchymal marker vimentin (Supplemental Figure 1, 
G and H, and Supplemental Table 2). In all cohorts, only a small 
fraction of mammary tumors (8%) was classified as carcinosarco-
Figure 1. Characterization of Brca1-mutant alleles. (A) 
DNA sequences and protein translations for the human 
BRCA1185delAG and mouse Brca1185stop mutations. Mutations 
are indicated in red. The number of aa until the STOP 
codon is indicated in parentheses. (B) DNA sequences 
and protein translations for the human BRCA15382insC 
and mouse Brca15382stop mutations. (C) Melting-curve 
genotyping of Brca1185stop-mutant mice. WT, Brca1+/+; Het, 
Brca1+/185stop; and Hom, Brca1185stop/185stop. (D) Melting-curve 
genotyping of Brca15382stop-mutant mice. WT, Brca1+/+; Het, 
Brca1+/5382stop, and Hom, Brca15382stop/5382stop. Data in C and D 
are plotted as the first negative derivative of the sample 
fluorescence versus temperature [–(d/dT)]. (E) Embry-
onic lethality of homozygous Brca1185stop mice. Images of 
Brca1+/+, Brca1185stop/+, and Brca1185stop/185stop embryos at E9.5. 
Scale bars: 1 mm. (F) Embryonic lethality of homozygous 
Brca15382stop mice. Images of Brca1+/+, Brca1+/5382stop, and 
Brca15382stop/5382stop embryos at E9.5. Het, heterozygous; 
Hom, homozygous.
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reached a volume of 200 mm3, tumor-bearing mice were treated 
with 50 mg/kg of the PARP inhibitor olaparib (AZD2281) for 28 
consecutive days or left untreated (Figure 3A).
We did not observe any differences in overall survival (OS) 
between mice that did not receive treatment; all mice had to be 
sacrificed within 25 days because of a large tumor (Figure 3B 
and Supplemental Figure 2). The KP and KB1P data have been 
published before (43). While mice carrying KP tumors did not 
respond at all to olaparib treatment (Figure 3, C and D; black 
curves; median OS [t50] = 10 days), the median OS of mice car-
rying KB1P tumors increased from 12 to 60 days following olapa-
rib treatment, and their tumors disappeared completely during 
the course of treatment (Figure 3, C and D; red curves). Howev-
er, KB1P tumors could not be fully eradicated with this 28-day 
olaparib dosing schedule, and tumors reappeared after the end 
of the treatment period.
The median OS of mice transplanted with KB1(5382stop)P 
tumors increased from 8 to 52 days after olaparib treatment (Fig-
ure 3, B and C; blue curves), which was significantly better than the 
median OS of mice transplanted with KP tumors [KB1(5382stop)P 
vs. KP, P < 0.0001, log-rank test]. No significant difference in OS 
was observed between mice with KB1(5382stop)P tumors and those 
KB1(5382stop)P (n = 20), and littermate control KB1P mice (n = 22) 
using array comparative genomic hybridization (aCGH). When 
applying the comparative module of the R package KCsmart (52, 
53), we did not detect any differences between recurrent CNAs in 
KB1(185stop)P or KB1P tumors (Figure 2D). We also could not find 
any differences in recurrent CNAs between KB1(5382stop)P and 
KB1P tumors (Figure 2E). On the basis of these results, we con-
clude that the histological and genetic features of KB1(185stop)P and 
KB1(5382stop)P mammary tumors are indistinguishable from each 
other and from those of KB1P control tumors.
Response of KB1(185stop)P mammary tumors to the PARP inhib-
itor olaparib. PARP inhibitors have been shown to be effective in 
breast and ovarian cancer patients carrying BRCA1/2 mutations 
(24–28). To study the response of KB1(185stop)P and KB1(5382stop)P 
tumors to PARP inhibition, we transplanted several indepen-
dent KB1(185stop)P, KB1(5382stop)P, BRCA1-deficient KB1P, and 
BRCA1-proficient K14-Cre p53fl/fl (referred to hereafter as KP) 
tumors into the fourth mammary gland of syngeneic female recip-
ient mice. This orthotopic transplantation model ensures that 
transplanted mouse mammary tumors retain the histomorpho-
logical features, molecular characteristics, and drug-sensitivity 
profiles of their spontaneous counterparts (54, 55). When tumors 
Figure 2. Development of genomically unstable mammary tumors in mice carrying Brca1185stop or Brca15382stop mutations. (A) TFS curves of KB1(185stop)P  
(n = 53, t50 = 186 days), KB1(5382stop)P (n = 60, t50 = 200 days) and KB1P (n = 128, t50 = 196 days) mice. P = 0.4510 (NS), by log-rank test for KB1(185stop)P  
versus KB1(5382stop)P. (B) Mammary TFS curves of KB1(185stop)P (n = 29, t50 = 184 days), KB1(5382stop)P (n = 31, t50 = 206 days), and KB1P (n = 68, 
t50 = 197 days). P = 0.0415 (NS), by log-rank test for KB1(185stop)P versus KB1(5382stop)P. (C) Distribution of mammary tumor types in KB1(185stop)P, 
KB1(5382stop)P, and KB1P mice. Numbers in the pie chart represent percentages. (D) Comparative KCsmart (KC) profiles of KB1(185stop)P and KB1P mouse 
mammary tumors. (E) Comparative KCsmart profiles of KB1(5382stop)P and KB1P tumors. t50, median survival; n, number of mice; Chr., chromosome.
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tin (Supplemental Table 3). Tumor-bearing mice were injected 
with the maximal tolerable dose of cisplatin and re-treated every 
2 weeks when the tumor volume was more than 50% of the start-
ing volume. If the tumor size after 2 weeks was smaller than 50%, 
treatment was postponed until the tumor reached 100% of the 
starting volume (Figure 4A). As some animals had to be sacrificed 
because of the toxic side effects of multiple cisplatin doses, we 
measured OS as well as TFS rates. Again, the data on the KP and 
KB1P controls have been previously published (43).
The median OS of mice transplanted with KB1(5382stop)P 
tumors was prolonged from 8 to 159 days after cisplatin treat-
ment (Figure 4, B and C; blue curves), which is identical to the 
response of mice transplanted with BRCA1-deficient KB1P tumors 
(43) [Figure 4, B and C; red curves, KB1(5382stop)P vs. KB1P; 
P = 0.9696 (NS), log-rank test]. Almost all mice transplanted with 
KB1(5382stop)P tumors had to be sacrificed because of cisplatin 
toxicity and not because of therapy resistance (Figure 4D). In 
contrast, the median OS of mice transplanted with KB1(185stop)P 
mammary tumors was only prolonged from 15 to 55 days after 
treatment with cisplatin (Figure 4, B and C; green curves) and 
was indistinguishable from the response of BRCA1-proficient 
tumors [Figure 4, B and C; black curves, KB1(185stop)P vs. KP, P = 
0.2550 (NS), log-rank test]. After an initial response to cisplatin, 
KB1(185stop)P tumors rapidly acquired resistance, and 62% of the 
mice needed to be sacrificed because of therapy-resistant tumors 
(Figure 4D). Remarkably, the response of KB1(185stop)P tumors 
with KB1P tumors after treatment with olaparib [KB1(5382stop)P 
vs. KB1P, P = 0.0905 (NS), log-rank test]. However, in contrast 
to KB1P tumors, KB1(5382stop)P tumors never completely disap-
peared during olaparib treatment, but rather entered a phase of 
tumor stasis (Figure 3D; blue curve).
Interestingly, mice transplanted with KB1(185stop)P tumors 
had a median OS of 26 days after the start of olaparib treatment 
(Figure 3C; green curve), which was significantly better than for 
mice with BRCA1-proficient KP tumors [KB1(185stop)P vs. KP, 
P = 0.0017,  log-rank test], but significantly worse than for mice 
with BRCA1-deficient KB1P tumors [KB1(185stop)P vs. KB1P, 
P < 0.0001, log-rank test]. While KB1(185stop)P tumors kept grow-
ing during the course of olaparib treatment, their growth rate 
was reduced compared with that of KP tumors (Figure 3D; green 
curve). Moreover, the olaparib response of KB1(185stop)P tumors 
was markedly worse than the response of KB1(5382stop)P tumors 
[Figure 3, C and D and Supplemental Figure 2; KB1(185stop)P 
vs. KB1(5382stop)P, P = 0.0012, log-rank test]. The response of 
KB1(185stop)P tumors to olaparib treatment closely resembled 
the response of K14-Cre Brca1fl/C61G p53fl/fl (referred to hereafter as 
KB1C61GP) mouse mammary tumors to olaparib (43).
Response of KB1(185stop)P mammary tumors to cisplatin. 
Since BRCA1-associated tumors are also known to be sensitive 
to platinum drugs (56), we transplanted several KB1(185stop)P, 
KB1(5382stop)P, KB1P, and BRCA1-proficient KP mammary 
tumors to study potential differences in their response to cispla-
Figure 3. Poor olaparib response of 
KB1(185stop)P mouse mammary tumors. 
(A) Schematic representation of olaparib 
treatment schedule. Tx, orthotopic trans-
plantation of fragments from spontaneous 
mouse mammary tumors; t0, start of 
treatment at a tumor volume of 200 mm3 
(100%). Mice received a daily dose of 50 
mg/kg olaparib i.p. for 28 consecutive days. 
(B) OS curves of mice transplanted with 
KB1(185stop)P, KB1(5382stop)P, KB1P, or 
KP tumors without treatment. t50, median 
OS. KB1(185stop)P: t50 = 15 days, n = 4 mice; 
KB1(5382stop)P: t50 = 8 days, n = 6 mice; 
KB1P: t50 = 12 days, n = 4 mice; KP: t50 = 
11 days, n = 4 mice. (C) OS curves of mice 
transplanted as indicated in B, after olapa-
rib treatment. KB1(185stop)P: t50 = 26 days, 
n = 12 mice; KB1(5382stop)P: t50 = 52 days,  
n = 10 mice; KB1P: t50 = 60 days, n = 7 mice; 
KP: t50 = 10 days, n = 5 mice. P = 0.0012,  
by log-rank test for KB1(185stop)P  
vs. KB1(5382stop)P; P < 0.0001, by log- 
rank test for KB1(185stop)P vs. KB1P;  
P = 0.0017, log-rank test for KB1(185stop)P  
vs. KP; P = 0.0905 (NS), by log-rank test 
for KB1(5382stop)P vs. KB1P; P < 0.0001, 
by log-rank test for KB1(5382stop)P vs. 
KP; and P = 0.0003, by log-rank test for 
KB1P vs. KP. (D) Comparison of relative 
mammary tumor volumes during a 28-day 
treatment with olaparib. Tumor volumes 
are relative to the tumor volume at the 
start of treatment (day 0, 100% = ±200 
mm3). Error bars indicate SEM.
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to cisplatin was significantly worse than that of KB1(5382stop)P 
tumors [Figure 4C; KB1(185stop)P vs. KB1(5382stop)P, P < 0.0001, 
log-rank test; Supplemental Figure 3, A–E]. The difference 
in response to cisplatin was even more pronounced when we 
compared the TFS of mice transplanted with KB1(185stop)P or 
KB1(5382stop)P mammary tumors (Supplemental Figure 3F).
To investigate whether these findings might also be rele-
vant for human patients, we evaluated the cisplatin sensitivity 
of several human BRCA1-mutant breast cancer cell lines. These 
included the SUM1315MO2 and HCC1937 cell lines, which carry 
BRCA1185delAG and BRCA15382insC mutations, respectively. In line with 
our observations in the mouse models, BRCA1185delAG-mutant SUM-
1315MO2 human breast cancer cells were less sensitive to cisplatin 
than were other BRCA1-mutated human breast cancer cell lines, 
including the BRCA15382insC-mutant HCC1937 cell line (Figure 4E). 
However, BRCA1185delAG-mutant SUM1315MO2 cells were more 
sensitive to cisplatin than were BRCA1-proficient U2OS cells or 
WT BRCA1–complemented HCC1937 cells (Figure 4E).
Figure 4. Poor cisplatin response of KB1(185stop)P mouse mammary tumors. (A) Schematic representation of cisplatin treatment schedule. t0, start of 
treatment with 6 mg/kg cisplatin i.v. at a tumor volume of 200 mm3, corresponding to a relative tumor volume (RTV) of 100%. t13, if the RTV on day 13 was 
≥50%, the mice received an additional treatment that was repeated every 2 weeks until an RTV of ≤50% was observed. If the RTV at t13 was ≤50%, re-treat-
ment was postponed until an RTV of >100% was observed. (B) OS curves of mice transplanted with KB1(185stop)P, KB1(5382stop)P, KB1P, or KP tumors 
without treatment. t50, median OS. KB1(185stop)P: t50 = 15 days, n = 4 mice; KB1(5382stop)P: t50 = 8 days, n = 6 mice; KB1P: t50 = 12 days, n = 4 mice; KP: t50 = 11 
days, n = 4 mice. (C) OS curves of mice transplanted as indicated in B after cisplatin treatment. KB1(185stop)P: t50 = 55 days, n = 35 mice; KB1(5382stop)P:  
t50 = 159 days, n = 47 mice; KB1P: t50 = 188 days, n = 18 mice; KP: t50 = 48 days, n = 21 mice. P < 0.0001, by log-rank test for KB1(185stop)P vs. KB1(5382stop)P;  
P < 0.0001, by log-rank test for KB1(185stop)P vs. KB1P; P = 0.2550 (NS), by log-rank test for KB1(185stop)P vs. KP; P = 0.9696 (NS), by log-rank test for 
KB1(5382stop)P vs. KB1P; P < 0.0001, by log-rank test for KB1(5382stop)P vs. KP; and P < 0.0001, by log-rank test for KB1P vs. KP. (D) Causes of death of 
tumor-bearing mice after treatment with cisplatin. The stacked bars indicate the percentage of mice that were sacrificed because of cisplatin-resistant 
mammary tumors, cisplatin-associated toxicity, or another (mesenteric) tumor. (E) Cisplatin sensitivity of various human BRCA1-mutated breast cancer cell 
lines, including SUM149PT (BRCA12288delT), SUM1315MO2 (BRCA1185delAG), and HCC1937 (BRCA15382insC). The U2OS osteosarcoma and WT BRCA1–complemented 
HCC1937 cell lines served as BRCA1-proficient controls. The experiment was performed in quadruplicate. Error bars indicate SEM.
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Therapy resistance of mouse and human BRCA1185delAG tumor 
cells is not explained by genetic reversion or loss of 53BP1. Giv-
en that BRCA1/2-deficient cell lines and ovarian tumors can 
become resistant to platinum compounds and olaparib through 
genetic reversion of the BRCA1/2 mutation (57–60), we first 
checked whether the Brca1185stop mutation was still present in 
platinum-resistant KB1(185stop)P tumors. Previously, we did 
not find any evidence for secondary Brca1 mutations in therapy- 
resistant KB1C61GP tumors (43). Similarly, Sanger sequencing 
and melting-curve genotyping revealed that all cisplatin-resis-
tant KB1(185stop)P tumors had retained the Brca1185stop muta-
tion (Supplemental Figure 4A and data not shown). On the 
basis of these results, we conclude that the observed platinum 
resistance in KB1(185stop)P mammary tumors is not caused 
by genetic reversion of the Brca1185stop mutation. Furthermore, 
we were able to derive several cisplatin-resistant clones of the 
BRCA1-mutated human breast cancer cell line SUM1315MO2, 
all of which also retained the BRCA1185delAG mutation (Supple-
mental Figure 4, B–D). In the absence of genetic reversion, 
loss of 53BP1 may also decrease the sensitivity of BRCA1- 
deficient mouse mammary tumors to olaparib and cisplatin (61). 
However, loss of 53BP1 does not explain the poor treatment 
response of the KB1(185stop)P mouse model, as platinum-resis-
tant and treatment-naive tumors all showed abundant expression 
of 53BP1 (Supplemental Figure 4, D and E, and data not shown).
RING-less BRCA1 expression in mouse and human BRCA1185delAG 
tumor cells. Since the response of KB1(185stop)P mouse mammary 
tumors to olaparib and cisplatin is similar to that of BRCA1-pro-
ficient KP tumors, we analyzed BRCA1 protein expression in 
KB1(185stop)P and KB1(5382stop)P mouse mammary tumors. 
Whereas KB1(5382stop)P tumors showed no detectable BRCA1 
protein (Figure 5A), all KB1(185stop)P tumors showed expres-
sion of a nearly full-length BRCA1 protein, indicating translation 
initiation downstream from the Brca1185stop mutation (Figure 5A). 
This finding suggests a discrepancy between the Brca1185stop allele 
of our mouse model and the human BRCA1185delAG allele, which 
was thought to express only a small N-terminal BRCA1 protein 
fragment of 38 aa (62).
Figure 5. RING-less BRCA1 expression in mouse and human BRCA1185delAG tumor cells. (A) BRCA1 protein expression in KB1(185stop)P mouse mammary 
tumors (left panel) compared with BRCA1-deficient KB1(5382stop)P and KB1P tumors (middle panels). A BRCA1-proficient KP tumor was used as a positive 
control (right panel). The asterisk in the far right panel indicates another KB1(185stop)P mouse mammary tumor. Expression of POLII was used as a loading 
control, and the positions of full-length (FL) and RING-less (ΔRING) BRCA1 and protein size markers are indicated. mBRCA1, murine BRCA1. (B) BRCA1 
protein expression in the BRCA1185delAG-mutant SUM1315MO2 human breast cancer cell line. As controls, SUM1315MO2 cells stably complemented with WT 
BRCA1 (WT) were depleted of endogenous BRCA1 by a BRCA1 3′-UTR–targeting shRNA (sh1) or depleted of both endogenous and ectopic BRCA1 using an 
shRNA targeting BRCA1 exon 11 (sh2). shNT, NT shRNA. Expression of POLII was used as a loading control, and the positions of full-length and RING-less 
BRCA1 and protein size markers are indicated. hBRCA1, human BRCA1. (C) Ribosome profiling of KB1(185stop)P mammary tumor cell lines indicated a 
translation start at methionine 90. Ribosome footprint profile along Brca1 exons 2 (containing methionine 1) and 6 (containing methionines 90 and 99) of 
2 different KB1(185stop)P mouse mammary tumor cell lines (lines 280 and 350) and a KP control. Methionines are indicated in green. Harr., harringtonine; 
M1, methionine 1; M90, methionine 90. (D) Schematic representations of BRCA1 peptides identified by mass spectrometry in Brca1 WT and KB1(185stop)P 
mouse mammary tumor cells.
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tumors from KB1P tumors and most likely explains the poor 
response to HRD-targeted therapy.
DNA damage response in mouse and human BRCA1185delAG tumor 
cells. The absence of genetic reversion of Brca1 or loss of 53BP1 in 
platinum-resistant KB1(185stop)P tumors suggests that RING-less 
BRCA1 protein has residual activity in the cellular response to 
DNA DSBs. In line with our observation that KB1(185stop)P tumors 
showed some response to PARP1 inhibition, treatment with olapa-
rib resulted in a DNA-damage increase similar to that seen in KB1P 
tumors (Figure 6A). However, we also found that the response to 
olaparib was eventually poor compared with that of KB1P tumors 
that were completely devoid of BRCA1 protein expression. To 
investigate whether RING-less BRCA1 protein has activity in DNA 
DSB repair via HR, we compared the ability to form RAD51 irradi-
ation-induced foci (IRIF) in short-term tumor cell cultures derived 
from KB1(185stop)P, KB1P, and BRCA1-proficient KP tumors. As 
shown previously (43), we could readily detect RAD51 IRIF in 
short-term cultures of HR-proficient KP tumor cells, but not in 
HR-deficient KB1P tumor cells (Figure 6, B and C). KB1(185stop)P 
tumor cells were also able to form RAD51 IRIF (Figure 6, B and 
C). Despite the statistically significant difference, the data from 
the short-term ex vivo cell-culture experiments were quite vari-
able. To gain further insight into the DNA damage response of 
KB1(185stop)P tumors, we continued our analysis in mouse mam-
mary tumor–derived cell lines. In agreement with the loss of 
BRCA1 function we observed, KB1(185stop)P cell lines had a defect 
in DNA end resection, as replication protein A (RPA) accumula-
tion at DSBs was impaired (Figure 6D). Indeed, KB1(185stop)P cell 
lines showed an initial deficiency in the repair of olaparib-induced 
DNA damage that was similar to that in KB1P cells (Figure 6E). 
Nevertheless, KB1(185stop) tumor cell lines showed RAD51 IRIF 
formation (Supplemental Figure 6A). In addition, human SUM-
1315MO2 breast cancer cells — carrying the BRCA1185delAG mutation 
— were also capable of forming RAD51 IRIF (Supplemental Figure 
6B). Thus, both mouse and human BRCA1185delAG tumor cells dis-
play HR activity in response to DNA damage, which could be the 
result of BRCA1-ΔRING expression.
To study whether the RING-less BRCA1 protein is function-
al in the DNA damage response, we checked for colocalization of 
BRCA1 with RAD51 after γ irradiation in cell lines derived from 
BRCA1-proficient, BRCA1-deficient, and Brca1185stop mouse mam-
mary tumors. While massive BRCA1/RAD51 colocalization was 
observed in BRCA1-proficient tumor cells, Brca1185stop tumor cells 
showed fewer and smaller BRCA1/RAD51 IRIF (Supplemental 
Figure 6A and data not shown). In contrast, BRCA1-deficient 
KB1P B11 cells showed no BRCA1/RAD51 IRIF at all (Supplemen-
tal Figure 6A). These data suggest that the RING-less BRCA1 pro-
tein is partially functional in the response to DNA damage. This 
may explain why human and mouse BRCA1185delAG tumor cells rap-
idly develop resistance to therapy that targets their HRD.
RING-less BRCA1 supports DNA repair via HR, resulting in 
reduced sensitivity of BRCA1185delAG tumor cells to PARP1 inhibition 
and cisplatin. To test whether mutant RING-less BRCA1 protein 
is indeed functionally important for BRCA1185delAG tumor cells, 
we performed BRCA1-knockdown experiments. Expression of 
RING-less BRCA1 in BRCA1185delAG-mutant SUM1315MO2 cells 
was markedly reduced by transduction with lentiviruses encod-
We therefore checked BRCA1 protein expression levels in 
the SUM1315MO2 human breast cancer cell line, which carries 
the BRCA1185delAG mutation. Remarkably, in BRCA1185delAG-mutant 
SUM1315MO2 cells, BRCA1 immunoblotting also detected a large 
protein that could be completely depleted using BRCA1-specific 
shRNAs (Figure 5B). In contrast to the truncated BRCA1 formed 
by KB1(185stop)P tumor cells, the BRCA1 protein expressed by 
SUM1315MO2 cells was clearly smaller than full-length WT 
BRCA1, indicating the absence of a substantial part of the pro-
tein. In addition, we could not detect the truncated protein with 
a BRCA1 Ab that binds the extreme N-terminus of BRCA1 (aa 
1–304; Supplemental Figure 5A). Together, these findings show 
that the BRCA1185delAG mutation can lead to production of a mutant 
BRCA1-ΔRING protein, which is probably devoid of its N-terminal 
RING domain (aa 1–109).
Whether the truncated BRCA1 variant expressed by 
KB1(185stop)P tumor also lacks the RING domain cannot be 
deduced from the minimal size difference observed with full-length 
BRCA1. In the absence of Abs of sufficient quality to distinguish 
between full-length and RING-less mouse BRCA1 protein, we 
performed ribosome profiling of cell lines derived from treatment- 
naive KB1(185stop)P and Brca1 WT KP mouse mammary tumors. 
We used harringtonine treatment to enrich for ribosomes at sites 
of translation initiation (63) and observed increased use of internal 
methionine 90 in KB1(185stop)P mouse mammary tumor cells com-
pared with KP cells (Figure 5C). Since these data suggest that the 
nearly full-length BRCA1 protein expressed in KB1(185stop)P mouse 
mammary tumors also lacks the RING domain, mass spectrometric 
experiments were performed to verify the loss of the RING domain. 
BRCA1 protein was immunoprecipitated using an Ab raised against 
aa 1328–1812 (64) and analyzed after size selection by denaturing 
polyacrylamide gel electrophoresis. Whereas BRCA1-RING (aa 
1–109) peptides were readily identified in WT BRCA1–expressing 
mouse tumor cells, they were not found in 2 different cell lines 
derived from KB1(185stop)P tumors (Figure 5D, Supplemental Fig-
ure 5B, and Supplemental Table 4). These data are compatible with 
the expression of RING-less BRCA1 in KB1(185stop)P cells. Given 
that even in WT BRCA1–expressing cells, not all possible RING pep-
tides could be detected by mass spectrometry, the precise composi-
tion of BRCA1-ΔRING variants could not be determined (Figure 5D 
and Supplemental Figure 5B). However, analysis of the most N-ter-
minal peptides identified supports a translation start at methionine 
90, as suggested by ribosome profiling.
To test whether resistance in KB1(185stop)P tumors was due 
to increased expression of BRCA1-ΔRING, we analyzed Brca1 
mRNA and BRCA1-ΔRING protein levels. Although we found sig-
nificantly increased Brca1 mRNA levels in most platinum-resistant 
KB1(185stop)P tumors compared with levels in untreated tumors 
(Supplemental Figure 5C), we did not find a consistent concom-
itant increase in RING-less BRCA1 protein levels (Supplemental 
Figure 5D). Moreover, expression of RING-less BRCA1 protein was 
also not significantly increased in SUM1315MO2 clones that had 
been selected for increased resistance to cisplatin (Supplemental 
Figure 5A). These findings imply that upregulation of RING-less 
protein expression is not strictly required for BRCA1185delAG-mutant 
tumor cells to become resistant to platinum therapy. Neverthe-
less, expression of RING-less BRCA1 distinguishes KB1(185stop)P 
Downloaded from http://www.jci.org on July 10, 2017.   https://doi.org/10.1172/JCI70196
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 9 1 1jci.org   Volume 126   Number 8   August 2016
able to complement SUM1315MO2 BRCA1185delAG-mutant cells 
depleted of endogenous BRCA1 expression by shRNAi in a clon-
al growth assay (Figure 7C and Supplemental Figure 7F). These 
data show that BRCA1185delAG cells are dependent on expression of 
the RING-less BRCA1 protein, possibly through its function in 
the repair of DNA DSBs.
To further analyze the effects of RING-less BRCA1 expres-
sion on treatment response, we used mouse KB1(185stop)P tumor 
cells, which were much less dependent on RING-less BRCA1 for 
proliferation than were SUM1315MO2 cells (data not shown). 
KB1(185stop)P tumor cell lines showed varying levels of sensitiv-
ity to olaparib and cisplatin, which seemed to correlate to some 
extent with expression levels of RING-less BRCA1 protein (Sup-
plemental Figure 8, A and B). Similar to SUM1315MO2 cells, 
KB1(185stop)P tumor cells also showed decreased RAD51 IRIF 
formation upon knockdown of Brca1 expression (Supplemental 
Figure 8, C and D). As stable suppression of human or mouse 
BRCA1 expression was not sufficiently efficient for long-term 
cytotoxicity experiments (data not shown), we used CRISPR/ 
Cas9 mutagenesis in KB1(185stop)P tumor cells to obtain 
ing 2 independent shRNAs against human BRCA1 (Figure 7A; sh1 
and sh2). Stable BRCA1 knockdown significantly inhibited the 
proliferation of BRCA1185delAG cells compared with cells transduc-
ed with a nontargeting (NT) shRNA (Supplemental Figure 7, A 
and B). In addition, we assessed the effect of BRCA1 knockdown 
on the formation of RAD51 IRIF. The percentage of BRCA1185delAG- 
mutant cells with RAD51 IRIF was significantly lower after 
BRCA1 knockdown (Figure 7B and Supplemental Figure 7C). 
This was not a result of alterations in the cell-cycle distribution, 
as stable knockdown of BRCA1 expression did not affect the 
number of BRCA1185delAG cells in the S or G2 phase (Supplemental 
Figure 7D). To obtain direct evidence of the functional activity of 
RING-less BRCA1 proteins, we generated a series of N-terminal 
truncation mutants of human BRCA1. Western blot analysis of 
these mutants suggests that the main human RING-less BRCA1 
protein is formed by alternative translation initiation at methi-
onine 297 (Supplemental Figure 7E). Interestingly, BRCA1-M297 
also appeared to be abundantly produced by cDNA constructs 
encoding BRCA1-M48 and BRCA1-M128 (Supplemental Figure 
7E). All N-terminal truncation variants of BRCA1 tested were 
Figure 6. DNA damage response in mouse and human 
BRCA1185delAG tumor cells. (A) Olaparib induced DNA 
damage in orthotopically transplanted KB1(185stop)P 
(185stop, n = 6), KB1P (n = 7), and KP (n = 6) tumors and 
nontreated controls (n = 4 for each genotype). Statistical 
significance was calculated using a 2-tailed, unpaired 
t test. (B) RAD51 IRIF in KB1(185stop)P, KB1P, and KP 
tumor cell suspensions. Nuclei (blue) with more than 
10 RAD51 foci (red) are indicated with red arrowheads. 
Red outlined areas highlight single-cell zoom-in (zoom, 
×63). Scale bars: 25 μm. (C) Quantification of RAD51 IRIF 
in KB1(185stop)P (n = 5), KB1P (n = 10), and KP (n = 7) 
tumors. Percentages were normalized to KP. Statistical 
significance was calculated using a 2-tailed, unpaired t 
test. (D) Accumulation of RPA at α tracks for 2 different 
KB1(185stop)P mouse mammary tumor cell lines (lines 
350 and 351) and KBP1 and KP controls. At least 100 
53BP1 tracks were evaluated per time point in 2 to 3 rep-
licate experiments, and statistical significance at 2 hours 
was calculated using Fisher’s exact test. (E) Olaparib 
induced DNA damage in 2 different KB1(185stop)P mouse 
mammary tumor cell lines (lines 350 and 351) and KB1P 
and KP controls. Cells were cultured in normal medium 
(day 0 [D0]) or treated for 24 hours with 10 μM olaparib 
and either analyzed directly (D1) or after a 3-day recovery 
period (D3). Red bars indicate the mean number of 53BP1 
foci in at least 120 cells, and data are representative of 
2 independent experiments. Statistical significance was 
calculated using a 2-tailed, unpaired t test.
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BRCA1-BRCT–encoding region of the Brca1185stop allele (Supple-
mental Figure 9, C–F).
To investigate whether disruption of the Brca1185stop allele also 
translates to a better treatment response in vivo, we performed 
orthotopic transplantation experiments in mice. The parental 
KB1(185stop)P tumor cells and their Brca1-knockout clone C3 grew 
into mammary tumors with a similar latency (data not shown), 
although untreated C3 tumors tended to proliferate at a somewhat 
slower rate once palpable (Supplemental Figure 10A). Strikingly, 
we also observed in vivo that inactivation of the Brca1185stop allele 
rendered KB1(185stop)P tumor cells much more sensitive to PARP 
inhibition and cisplatin (Figure 7, G and H, and Supplemental Fig-
evidence for the relevance of RING-less BRCA1 in therapy 
response. We targeted the BRCA1-BRCT–encoding region using 
a single-guide RNA (sgRNA) specific for exon 21 of Brca1. In 2 of 
3 KB1(185stop)P clones analyzed (clones C1 and C3), frameshift 
mutations in exon 21 of the Brca1185stop allele resulted in loss of 
RING-less BRCA1 protein expression (Supplemental Figure 9, 
A and B). Similar to Brca1 knockdown, these frameshift muta-
tions disrupted RAD51 IRIF formation (Figure 7D and data not 
shown). In addition, inactivation of RING-less BRCA1 resulted 
in dramatically increased sensitivity to both olaparib and cis-
platin (Figure 7, E and F). These results were confirmed using 
another sgRNA targeting the Cas9 nuclease to exon 17 in the 
Figure 7. BRCA1185delAG tumor cells are dependent on RING-less BRCA1 for proliferation, DNA damage signaling, and treatment response. (A) BRCA1 pro-
tein levels after BRCA1 knockdown in BRCA1185delAG-mutant SUM1315MO2 tumor cells. –, no shRNA. Expression of POLII was used as a loading control, and 
protein size markers are indicated. (B) Quantification of RAD51 IRIF–positive SUM1315MO2 cells after BRCA1 knockdown as in A. The percentage of cells 
with 10 or more RAD51 foci was evaluated for at least 300 cells per condition. Statistical significance was calculated using Fisher’s exact test, and results 
are representative of 2 independent experiments. (C) Complementation of SUM1315MO2 cells by stably transfected cDNA constructs expressing WT BRCA1 
(WT) or BRCA1 N-terminal truncation variants (M48, M128, or M297). NTF, nontransfected control. Cells were assayed for clonal growth after transduction 
with the BRCA1 3′-UTR–targeting shRNA (sh1) or the NT shRNA (shNT) control. P = 0.0005 by 2-tailed, unpaired t test for NTF control shNT versus sh1. 
Significant complementation of proliferation is indicated by **P < 0.01 or #P < 0.0001. Results shown are representative of 2 independent experiments. 
(D) RAD51 IRIF formation in Brca1 WT (KP) cells, the KB1(185stop)P (288) cell line, and its Brca1 deficient subclone C3 (288-C3). Cells were irradiated with 10 
Gy, and RAD51 foci formation in S and G2 phases was compared with a nonirradiated control (no IR). Red bars indicate the mean number of foci in at least 
116 EdU-positive cells. P value was determined using a 2-tailed, unpaired t test, and data are representative of 2 independent experiments. (E and F) IC50 
values of KB1(185stop)P cell line 288 and subclones C1-3 for olaparib (E) and cisplatin (F). Error bars indicate the SD for 3 independent experiments. (G and 
H) OS of mice transplanted with KB1(185stop)P cell lines 288 and 288-C3 and treated with 100 mg/kg AZD2461 daily for 28 consecutive days (G) or with  
6 mg/kg cisplatin on days 0 and 14 (H), or untreated (G). P values were calculated using the log-rank test.
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Supplemental Figure 11, A–C). In line with the data from the 
KB1(185stop)P mouse model, PDX179 did not respond well to 
olaparib (Figure 8C and Supplemental Figure 11B). Thus, resid-
ual activity of RING-less BRCA1 may cause resistance to PARP 
inhibition in human tumors as well. The data for PDX127 illus-
trate that also BRCA1185delAG tumors with undetectable levels of 
(RING-less) BRCA1 expression may also show a poor response 
to treatment (Figure 8C and Supplemental Figure 11A), suggest-
ing the existence of multiple mechanisms of resistance. Of note, 
similarly low expression levels of RING-less BRCA1 did not pre-
vent regression of PDX230 tumors upon olaparib treatment (Fig-
ure 8C and Supplemental Figure 11C). We found no evidence of 
genetic reversion in any of the olaparib-resistant tumors (Figure 
8, A and B, and data not shown). The results from the BRCA1185delAG 
PDX tumors support the data from our mouse models and tissue 
culture experiments and warrant a careful evaluation of response 
data from BRCA1185delAG breast and ovarian cancer patients treated 
with platinum drugs or PARP inhibitors.
Discussion
We have used genetically engineered mouse models mimicking 
the 2 most common BRCA1 founder mutations, BRCA1185delAG and 
BRCA15382insC, to study the effects of these mutations on tumor 
development and therapy response and resistance. While mice 
carrying the Brca1185stop or Brca15382stop mutation develop similar 
types of mammary carcinomas, Brca1185stop tumors respond signifi-
cantly worse to HRD-targeted therapy than do Brca15382stop tumors 
and rapidly develop therapy resistance. It has previously been 
shown that secondary mutations in BRCA1 can mediate resistance 
to platinum-based chemotherapy in BRCA1185delAG ovarian carcino-
mas (59, 60). However, we could not detect genetic reversion of 
the Brca1185stop mutation in any of the platinum-resistant Brca1185stop 
ure 10, B and C). We used the PARP inhibitor AZD2461, which 
is a poor P-glycoprotein substrate, to avoid resistance caused by 
increased drug efflux (61). Mammary tumors derived from trans-
planted KB1(185stop)P cells only showed a moderate response to 
28 days of treatment with AZD2461, with an increase of median 
survival from 21 to 32.5 days. In contrast, the median latency of 
tumors derived from the Brca1-knockout KB1(185stop)P clone C3 
doubled from 35 to 72 days. Similarly, inactivation of the Brca1185stop 
allele resulted in a much more durable response to cisplatin. 
Two doses of cisplatin increased the median latency period for 
KB1(185stop)P outgrowths to 48 days, whereas mice bearing C3 
tumors showed an increase in median survival out to 93 days. 
Thus, expression of RING-less BRCA1 variants can indeed lead to 
decreased sensitivity to HRD-targeted therapy.
Decreased sensitivity of BRCA1185delAG PDX tumors expressing 
RING-less BRCA1 to PARP1 inhibition. Although our data show 
that expression of RING-less BRCA1 can lead to HRD-targeted 
therapy resistance, it is not yet clear whether this is a relevant 
resistance mechanism in human cancer patients. To gain insight 
into the potential clinical relevance of RING-less BRCA1, we 
analyzed BRCA1 protein expression and olaparib response in 3 
different BRCA1185delAG patient-derived xenograft (PDX) models 
of breast cancer. In one of these models, PDX179, we detected 
putative RING-less BRCA1 protein (Figure 8, A and B). Similar 
to SUM1315MO2 cells, PDX179 tumors expressed a nearly full-
length BRCA1 variant that was not detected by an Ab raised 
against the BRCA1 N-terminus. In the 2 other BRCA1185delAG mod-
els, PDX127 and PDX230, we did not detect noticeable levels of 
RING-less BRCA1 expression. To investigate whether expres-
sion of RING-less BRCA1 would correlate with decreased sensi-
tivity of BRCA1185delAG tumors to PARP inhibition, we performed 
olaparib treatment studies for all 3 PDX models (Figure 8C and 
Figure 8. A RING-less BRCA1–expressing BRCA1185delAG PDX model of breast cancer shows poor response to olaparib. (A and B) Western blot analysis of 
BRCA1 expression in 3 different BRCA1185delAG PDX models of breast cancer and BRCA1-deficient (–) and BRCA1-proficient (+) controls, using the BRCA1 Abs 
MS110 (A; epitope: aa 1–304) and 9010 (B; epitope: aa 305–325). Expression of POLII was used as a loading control, and protein size markers are indicated. 
(C) Waterfall plot showing the olaparib response of individual PDX mammary tumors after 31 (PDX127, PDX230) or 33 (PDX179) days of treatment (50 mg/
kg olaparib, i.p., 5 days/week). (D) Quantification of RAD51 foci in olaparib- or vehicle-treated BRCA1185delAG PDX tumors. Percentages of S/G2-phase cells 
(geminin+) with 5 or more RAD51 foci (RAD51+) were determined on FFPE tumor samples for each PDX model. Error bars indicate the SD for 3 biological 
replicates, and P values were determined using a 2-tailed, unpaired t test.
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intertumoral heterogeneity in both the presence (and abundance) 
of preexisting secondary BRCA1 mutations and the expression 
levels of RING-less BRCA1 protein. Furthermore, we observed 
substantial differences among tumors in the levels of RING-less 
BRCA1 expression, which may also exist between BRCA1185delAG 
breast and ovarian cancers. Genetic reversion might be the pre-
ferred mechanism of therapy resistance in tumors with preexist-
ing secondary BRCA1 mutations and weak or no expression of the 
RING-less BRCA1 protein.
The existence of RING-less BRCA1 proteins in mouse and 
human BRCA1185delAG tumor cells appears to be the result of 
internal translation reinitiation at downstream start codons, as 
has previously been observed in transient transfection exper-
iments with human BRCA1 minigenes (66). Translation initi-
ation at methionine 297 of human BRCA1 could also explain 
why  BRCA1185delAG mRNA is not degraded by NMD (66, 67). The 
mutant RING-less BRCA1 protein produced in our genetically 
engineered Brca1185stop mouse model is somewhat larger than its 
human counterpart, most likely because of usage of the more 
upstream alternative start codon at methionine 90 in the mouse 
Brca1 coding sequence.
Differences in therapy response between BRCA1 founder muta-
tions. While patients with BRCA1-mutated ovarian cancer have 
a better prognosis after platinum-based chemotherapy than do 
nonmutation carriers (15–18), some heterogeneity in survival 
appears to exist among carriers of different BRCA1 mutations 
(16). Survival of ovarian cancer patients carrying the BRCA1185delAG 
mutation has been compared with that of BRCA15382insC patients, 
but, unfortunately, no conclusions could be drawn because of the 
small number of patients with a BRCA15382insC mutation (16). Our 
data indicate that the poor therapy response of Brca1185stop mouse 
mammary tumors is mediated by residual activity of the RING-
less BRCA1 protein. Therefore, we predict that RING-less BRCA1 
expression may also have consequences for the clinical response 
of BRCA1185delAG patients to DNA-damaging therapy.
Expression of a RING-less BRCA1 protein may not be limit-
ed to BRCA1185delAG tumors, but could also occur in tumors carry-
ing other truncating mutations in the N-terminus of BRCA1. Our 
data suggest that the presence of a RING-less BRCA1 protein in 
these tumors can serve as a marker to predict poor response to 
treatment with platinum or PARP inhibitors. PARP inhibitors are 
currently being tested in phase III clinical trials for BRCA1/2- 
associated breast cancers and approved for advanced BRCA1/2- 
associated ovarian cancers. Although pathogenic germline 
mutations in BRCA1 or BRCA2 are thus far the best predictors of 
PARP inhibitor sensitivity, it will be important to critically eval-
uate the treatment response of tumors with mutations affecting 
the N-terminus of BRCA1. This type of analysis will require large 
numbers of patients carrying specific BRCA1 founder mutations 
and therefore remains a challenge for the future. Meanwhile, 
our genetically engineered and PDX mouse models offer ideal 
platforms for testing hypotheses on therapy response and resis-
tance. Knowledge gained from these models could contribute 
to more accurate predictions of therapy responses of different 
BRCA1 mutation carriers, help to prevent ineffective treatment, 
and lead to earlier development and implementation of alterna-
tive therapeutic agents.
mouse mammary tumors. Also, in multiple cisplatin-resistant 
clones of the human BRCA1185delAG breast cancer cell line SUM-
1315MO2, no reversal of the mutation was found. Instead, we 
noticed that mouse and human BRCA1185delAG tumor cells produced 
RING-less BRCA1 proteins, which are involved in the develop-
ment of platinum and PARP inhibitor resistance through their 
activity in the DNA damage response.
A role for RING-less BRCA1 proteins in therapy response and 
resistance. While it was thus far thought that the BRCA1185delAG 
frameshift mutation only leads to the formation of a small N-ter-
minal protein of 38 aa, we detected nearly full-length, RING-less 
BRCA1 protein in Brca1185stop mouse mammary tumors. This was 
not merely an artifact of our genetically engineered mouse model, 
since we could also detect RING-less BRCA1 in human breast can-
cer cells carrying the BRCA1185delAG mutation.
Brca1185stop tumors did not require secondary Brca1 mutations 
to become resistant to PARP inhibition or cisplatin, because resid-
ual activity of the RING-less BRCA1 protein was already suffi-
cient to withstand these types of targeted therapeutics. This find-
ing extends the conclusions of our previous work with Brca1C61G 
tumors, which expressed a full-length BRCA1 protein containing 
a missense mutation in the RING domain (43). Our data indicate 
that RING-less BRCA1 is not completely functional in HR, but 
that this protein still supports RAD51 IRIF formation. Thus, while 
insufficient for embryonic survival and tumor suppression, the 
residual activity of the RING-less BRCA1 protein can contribute to 
the rapid development of therapy resistance in Brca1185stop tumors. 
Our data suggest that there is no strict requirement for upregula-
tion or stabilization of RING-less BRCA1 protein levels for resis-
tance to occur. In both human and mouse breast cancer cells, 
RING-less BRCA1 supported RAD51 IRIF formation, demonstrat-
ing its functional significance. Moreover, deletion of the Brca1185stop 
allele rendered KB1(185stop)P tumor cells sensitive to cisplatin and 
PARP inhibition. To further investigate the potential relevance of 
our findings for human cancer patients, we analyzed 3 indepen-
dent BRCA1185delAG PDX models of breast cancer for expression 
of RING-less BRCA1 and response to PARP inhibition. In con-
cordance with the data from our genetically engineered mouse 
models and the SUM1315MO2 cell line, a PDX model expressing 
RING-less BRCA1 showed progressive disease in the presence 
of the PARP inhibitor olaparib. Thus, human tumors expressing 
RING-less BRCA1 may also be resistant to HRD-targeted therapy. 
Although we detected no RING-less BRCA1 expression in another 
PDX model that showed resistance to olaparib, we found no evi-
dence for genetic reversion of the BRCA1185delAG mutation in any of 
the PDX tumors.
Why, then, are secondary BRCA1 mutations still observed in 
therapy-resistant BRCA1185delAG human ovarian carcinomas? One 
possibility is that these secondary BRCA1 mutations are already 
present in rare cells of primary carcinomas, possibly because of 
genomic instability, and subsequently selected under the pres-
sure of chemotherapy. This has been described before for chronic 
myeloid leukemia, in which BCR-ABL mutations that confer ima-
tinib resistance are already present in a minority of tumor cells 
before exposure to the drug (65). In addition, the level of RING-
less BRCA1 protein in untreated BRCA1185delAG human ovarian 
carcinomas is currently unknown. There could be considerable 
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libraries were sequenced on an Illumina HiSeq 2000 system. A 
detailed protocol is described in the Supplemental Methods.
Mass spectrometric analysis of mouse RING-less BRCA1 protein. 
Immunoprecipitated BRCA1 was subjected to nanoflow liquid chro-
matography–tandem mass spectrometry (LC-MS/MS) on an 1100 
Series Capillary LC System (Agilent Technologies) coupled to an 
LTQ Orbitrap XL Mass Spectrometer (Thermo Fisher Scientific). 
Detailed information on the experimental procedures is provided in 
the Supplemental Methods.
Sanger sequencing. Sequencing was done using the BigDye Termi-
nator v3.1 Cycle Sequencing Kit (Applied Biosystems). Sequencing was 
performed on both genomic DNA and cDNA from tumors and spleens. 
Primer information is provided in the Supplemental Methods.
Array comparative genome hybridization and data analysis. Genom-
ic DNA samples from tumors and spleens were labeled with the Nim-
bleGen Dual-Color DNA Labeling Kit and hybridized to the Nim-
bleGen 12-plex 135K full-genome mouse custom NKI array. Details of 
the analysis are described in the Supplemental Methods.
Clonogenic survival assays. Human and mouse cancer cell lines 
were plated onto 12-well plates at densities of 15,000 (SUM1315MO2, 
SUM149PT, HCC1937, and UWB.289.1); 6,000 (U2OS); and 600–
1,000 (KB1(185stop)P) cells per well, respectively. For comparisons of 
KB1(185stop)P, KP, and KB1P cell lines, 1,000 KB1(185stop)P and KP 
cells and 3,000 KB1P B11 cells were plated onto 6-well plates. Twelve 
hours to one day after plating, a range of concentrations of cisplatin 
(Sigma-Aldrich or Mayne Pharma) in saline or olaparib (AZD2281; 
Selleck Chemicals or AstraZeneca) in DMSO was added to the cells. 
Cells were also treated with only saline or DMSO as the “no-drug 
control.” Cells were allowed to grow in the presence of the drug for 
7 days and stained with 0.1% to 1% crystal violet. Clonogenic survival 
was determined by measuring the absorbance of crystal violet at 590 
to 595 nm. Full details on cell culture conditions are provided in the 
Supplemental Methods.
BRCA1- and Brca1-knockdown experiments. Cells were transduced 
with pLKO-puro shRNA viruses (TRC library clones; Thermo Scien-
tific Open Biosystems) targeting human BRCA1 or mouse Brca1 or an 
NT control. After puromycin selection, cells were assayed for γ irra-
diation–induced DNA repair foci or seeded for clonal growth. SUM-
1315MO2 cells were incubated with CellTiter-Blue (Promega) or fixed 
and stained with crystal violet after 2 weeks of clonal growth, and flu-
orescence or absorbance were measured. Full details are provided in 
the Supplemental Methods.
CRISPR/Cas9-mediated inactivation of the Brca1185stop allele. CRISPR/ 
Cas9 mutagenesis was performed as described previously (68). Brief-
ly, KB1(185stop)P mouse mammary tumor cells were transiently trans-
fected with a modified pX330 CRISPR/Cas9 plasmid (Addgene plas-
mid 42230) containing a puromycin resistance marker and targeting 
the BRCT-encoding region of Brca1. After 2 days of puromycin selec-
tion (1.8 μg/ml), cells were seeded at clonal density, and colonies were 
selected for further analyses and experiments. Full details are provid-
ed in the Supplemental Methods.
Immunoblotting. Tumor protein lysates were made by using a 
microhomogenizer and radioimmunoprecipitation assay (RIPA) lysis 
buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.1% deoxycho-
late, 1% NP40), complemented with 2× Complete Protease Inhibitor 
Cocktail (Roche) and Pefabloc (Roche; 1 mg/ml). Following homoge-
nization on ice, tumor lysates were kept on ice for 30 minutes. After a 
Methods
Generation of Brca1185stop- and Brca15382stop-mutant mice. Nonchemical-
ly modified deoxyribonucleotides (Sigma-Genosys) were used to 
introduce the Brca1185stop (5′-ATGCAGAAAATCTTAGAGTAGGC-
GATCTGGTAAGTCAACA-3′) and Brca15382stop (5′-CAAGGCGATC-
CAGAGAATCAGGACCGGGAAAAGGTAAAGTC-3′) mutations into 
mESCs. The procedures for the introduction of oligonucleotides into 
mESCs, selection for G418-resistant colonies, and identification and 
purification of modified cells have been described previously (44–47). 
The resulting ESCs were injected into C57BL/6J blastocysts to pro-
duce chimeric males, which were mated with FVB females to generate 
Brca1+/185stop and Brca1+/5382stop mice. Brca1+/185stop and Brca1+/5382stop mice 
were bred with K14-Cre Brca1fl/fl p53fl/fl (KB1P) animals (48) to generate 
K14-Cre Brca1185stop/fl p53fl/fl [KB1(185stop)P] and K14-Cre Brca15382stop/fl 
p53fl/fl [KB1(5382stop)P] mice. Full details on the generation of the 
Brca1185stop and Brca15382stop alleles and mouse genotyping are provided 
in the Supplemental Methods.
Embryo isolations. Timed matings were performed between 
Brca1185stop or Brca15382stop heterozygous male and female mice. The 
impregnated females were sacrificed at various time points after 
conception, and their uteri were isolated in ice-cold PBS. The 
embryos were isolated by removing the muscular wall of the uterus, 
Reichert’s membrane, and the visceral yolk sac. The visceral yolk 
sac was used for genotyping.
Orthotopic transplantations and drug interventions. Small frag-
ments of mammary tumors from KP, KB1P, KB1(185stop)P, or KB1 
(5382stop)P mice were transplanted orthotopically into FVB:129/
Ola F1 hybrid female mice as described previously (55). To generate 
mouse mammary tumors from KB1(185stop)P cell lines, 500,000 
cells were transplanted into the fourth right mammary fat pad of 
9-week-old female athymic nude RjOrl:NMRI-Foxn1nu/Foxn1nu mice 
(Janvier Labs) in 50 μl Matrigel (Corning) and PBS (1:1). When the 
tumor volume exceeded 200 mm3, the mice were treated with the 
maximum tolerated dose (MTD) of cisplatin, olaparib, or AZD2461 
(23, 55, 61). To study resistance, animals received additional doses of 
cisplatin when tumors grew back to a size of 200 mm3. Animals were 
sacrificed when the tumor volume exceeded 1,500 mm3 or when they 
became ill from drug toxicity.
The 3 PDX models used in this study were derived from PARP 
inhibitor–naive germline BRCA1185delAG carriers presenting with hor-
mone receptor–negative, HER2-negative, triple-negative breast 
cancers (TNBCs). The patient from whom PDX179 was derived had 
received cisplatin prior to tumor implantation into nude mice. PDX127 
and PDX179 were derived from metastatic lesions, and PDX230 was 
derived from a primary tumor (additional clinical history is provided 
in the Supplemental Information). Tumors were s.c. implanted into 
6-week-old female athymic nude HsdCpb:NMRI-Foxn1nu/Foxn1nu 
mice (Envigo). Animals were supplemented with 1 μmol/l 17β-estra-
diol (Sigma-Aldrich) in their drinking water. Upon xenograft growth, 
tumor tissue was reimplanted into recipient mice, which were ran-
domized for olaparib or vehicle treatment, starting at tumor volumes 
between 50 and 500 mm3. Treatment consisted of either vehicle (10% 
v/v DMSO in 10% w/v Kleptose (Roquette Laisa España) [HP-β-CD] 
in purified, deionized water) or 50 mg/kg olaparib in vehicle, adminis-
tered i.p. 5 days per week.
Ribosome profiling of tumor cell lines. Ribosome-protected RNA 
fragments were isolated essentially as described before (63), and 
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